EUVIMEDEUVIMED entdecken
Open Access

Cystic fibrosis macrophage function and clinical outcomes after elexacaftor/tezacaftor/ivacaftor

Shuzhong Zhang, Chandra L Shrestha, Frank Robledo-Avila iD, Devi Jaganathan, Benjamin L Wisniewski, Nevian Brown, Hanh Pham, Katherine Carey, Amal O Amer, Luanne Hall-Stoodley, Karen S McCoy, Shasha Bai und 2 weitere

European Respiratory Journal · 2023

DOI: 10.1183/13993003.02861-2021 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Respiratory Journal, 2023. Verfasst von Shuzhong Zhang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Center for Microbial Pathogenesis, The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA. Hauptthemen laut MEDLINE: Cystic Fibrosis. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIAID NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Abnormal macrophage function caused by dysfunctional cystic fibrosis transmembrane conductance regulator (CFTR) is a critical contributor to chronic airway infections and inflammation in people with cystic fibrosis (PWCF). Elexacaftor/tezacaftor/ivacaftor (ETI) is a new CFTR modulator therapy for PWCF. Host–pathogen and clinical responses to CFTR modulators are poorly described. We sought to determine how ETI impacts macrophage CFTR function, resulting effector functions and relationships to clinical outcome changes.

Methods

Clinical information and/or biospecimens were obtained at ETI initiation and 3, 6, 9 and 12 months post-ETI in 56 PWCF and compared with non-CF controls. Peripheral blood monocyte-derived macrophages (MDMs) were isolated and functional assays performed.

Results

ETI treatment was associated with increased CF MDM CFTR expression, function and localisation to the plasma membrane. CF MDM phagocytosis, intracellular killing of CF pathogens and efferocytosis of apoptotic neutrophils were partially restored by ETI, but inflammatory cytokine production remained unchanged. Clinical outcomes including increased forced expiratory volume in 1 s (+10%) and body mass index (+1.0 kg·m −2 ) showed fluctuations over time and were highly individualised. Significant correlations between post-ETI MDM CFTR function and sweat chloride levels were observed. However, MDM CFTR function correlated with clinical outcomes better than sweat chloride.

Conclusion

ETI is associated with unique changes in innate immune function and clinical outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisHumansCystic Fibrosis Transmembrane Conductance RegulatorChloridesChloride Channel AgonistsMutationMacrophagesPyrazolesPyridinesPyrrolidinesAminophenolsQuinolonesIndolesBenzodioxoles

Substanzen

Cystic Fibrosis Transmembrane Conductance RegulatorChloridesChloride Channel AgonistselexacaftorPyrazolesPyridinesPyrrolidinesivacaftorAminophenolsQuinolones

Autor:innen und Institutionen

  • Center for Microbial Pathogenesis, The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.
  • Center for Microbial Pathogenesis, The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA btkopp@emory.edu.
  • Division of Pulmonary Medicine, Nationwide Children's Hospital, Columbus, OH, USA.
  • Department of Microbial Infection and Immunity, The Ohio State University, Columbus, OH, USA.
  • Infectious Disease Institute, The Ohio State University, Columbus, OH, USA.
  • Pediatric Biostatistics Core, Emory University School of Medicine, Atlanta, GA, USA.

ORCID-Profile: Frank Robledo-Avila

Förderung

  • NHLBI NIH HHS
  • NIAID NIH HHS
  • NCATS NIH HHS
  • Cystic Fibrosis Foundation
  • National Institutes of Health

Zitieren

APA

Zhang, S., Shrestha, C. L., Robledo-Avila, F., Jaganathan, D., Wisniewski, B. L., Brown, N., Pham, H., Carey, K., Amer, A. O., Hall-Stoodley, L., McCoy, K. S., Bai, S., Partida-Sanchez, S., & Kopp, B. T. (2023). Cystic fibrosis macrophage function and clinical outcomes after elexacaftor/tezacaftor/ivacaftor. European Respiratory Journal. https://doi.org/10.1183/13993003.02861-2021

Vancouver

Zhang S, Shrestha CL, Robledo-Avila F, Jaganathan D, Wisniewski BL, Brown N, et al. Cystic fibrosis macrophage function and clinical outcomes after elexacaftor/tezacaftor/ivacaftor. European Respiratory Journal. 2023. doi:10.1183/13993003.02861-2021

BibTeX
@article{Zhang2023,
  author = {Zhang, Shuzhong and Shrestha, Chandra L and Robledo-Avila, Frank and Jaganathan, Devi and Wisniewski, Benjamin L and Brown, Nevian and Pham, Hanh and Carey, Katherine and Amer, Amal O and Hall-Stoodley, Luanne and McCoy, Karen S and Bai, Shasha and Partida-Sanchez, Santiago and Kopp, Benjamin T},
  title = {Cystic fibrosis macrophage function and clinical outcomes after elexacaftor/tezacaftor/ivacaftor},
  journal = {European Respiratory Journal},
  year = {2023},
  doi = {10.1183/13993003.02861-2021}
}
Kostenlos starten →